Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

While products like growth factor skincare already have demonstrated benefits, this is only the beginning, according to Prithwiraj Maitra, PhD.

What Dermatologists Need to Know About the Future of Regenerative Aesthetics

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Dual-Energy Approach Boosts Skin Hydration

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

This review of the latest dermatologic studies includes insights into epidermolysis bullosa for primary care providers, patient-reported impact of atopic dermatitis on pediatric and adolescent patients, and more.

Journal Digest: April 23

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: April 22, 2025

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Miranda Uzoma Ewelukwa, MD, FAAD, reviews how skin of color representation has evolved in dermatology, however, more advocacy is still needed. 

Improving Representation of Skin of Color in Dermatology  

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

I have not considered the role of AI technology in Mohs surgery

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

A poster session and ACMS keynote speaker Anant Madabhushi, MS, PhD, both delve into the use of AI in Mohs surgery. 

POLL: Do You Think AI Technology Can Enhance the Mohs Surgery Workflow?

In a groundbreaking initiative that bridges science and creativity, John Zampella, MD, FAAD, associate professor of dermatology at NYU School of Medicine, and Mitchell Hanson, an MD/MPH candidate at the Medical College of Georgia, have introduced an innovative art showcase at the American Academy of Dermatology (AAD) Annual Meeting. The program seeks to explore how art can deepen connections within the dermatological community and enhance the understanding of identity, illness, and healing.

The project, with this year’s theme of “Self-Identity, Medicine, and Dermatology,” originated from a simple idea: incorporating artistic expression into the professional landscape of dermatology. Inspired by an AAD initiative called The Art of the Skin, spearheaded by Susan Taylor, MD, the AAD’s current president, Zampella and Hanson saw an opportunity to create something new. “This is the first year it’s ever happened,” Zampella said in a recent interview with 

. “I thought, how could we integrate art into some of the stuff that we’re doing?”

Hanson, who is not only a medical student but also an artist and LGBTQ+ advocate, took the idea and ran with it. Drawing on his past experience illustrating posters and even crafting original visuals for a TEDx talk, Hanson designed a submission-based art show inviting medical students and residents to express their identities and experiences through visual media.

The result was a compelling collection of over 20 diverse submissions—including paintings, textiles, mixed media, digital art, and photography. “I was really impressed with the talent that exists in our students and residents,” Zampella reflected. “There was some really high-quality, robust artwork with real thought and real talent.”

Hanson emphasized the inclusive, welcoming tone of the exhibit. “I wanted everyone to feel like they had a space there to talk and be seen,” he said. He noted that showcasing identity in dermatology is particularly powerful, as the skin is such a visible, personal part of the human body. “I wanted to leave it open to interpretation what that meant for medicine and dermatology.”

The impact extended beyond the artistic experience itself. Many students and attendees who might otherwise have felt intimidated by the scale of the AAD conference found a place to connect. “It lets everyone feel more like they are a part of the community,” said Hanson. “They have something to contribute, which I love.”

Clinically, the initiative is supported by research that links art exposure with improved diagnostic and communication skills. “It’s been shown in prior studies, at least with residents, to enhance visual diagnostic skills,” Hanson noted. “It’s also helped with cultural competency… and with students being able to display empathy and check their own biases.”

Zampella highlighted another critical dimension: preventing physician burnout. “Medical training and the practice of medicine beat a lot of the life out of you… People don’t have a lot of time to do hobbies or work on themselves. We want to encourage people here to maintain those other hobbies and skills outside of medicine.”

One particularly poignant piece showcased a sponge wiping away a surface to reveal a vibrant LGBTQ+ pride flag underneath—symbolizing the interplay between skin disease, identity, and visibility. “Instead of removing the dirty skin, it’s like, ‘This is who I am,’” Zampella said. “It hit all the things—what patients feel, how the artist feels, and how skin disease is not something necessarily to be washed away, but part of you.”

Looking ahead, both Zampella and Hanson hope the initiative continues to grow, potentially becoming a formal session at future AAD meetings. “If it stayed the way it is and still existed in 5 years, I’d be thrilled,” said Zampella. Hanson echoed the sentiment, but both expressed an ambition to expand the model across specialties: “I would like to see this on a broader display… I think art could be such a powerful tool to actually help students practice empathy, perspective-taking, and meaning in ways never done before.”

By elevating art in a medical context, this program not only humanizes dermatology but redefines how medicine itself can be practiced—with creativity, vulnerability, and vision.

An innovative art showcase at the American Academy of Dermatology Annual Meeting, led by John Zampella, MD, and Mitchell Hanson, MD/PhD candidate, integrates art into dermatology to enhance understanding of identity, illness, and healing. The initiative, inspired by The Art of the Skin, features diverse submissions from medical students and residents, fostering community and inclusivity. It also supports improved diagnostic skills, cultural competency, and empathy. The program aims to prevent physician burnout and hopes to expand across medical specialties, redefining medicine with creativity and vision.

Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology.

Art Meets Medicine in Bold New AAD Showcase

A recent study reviewed cosmeceutical trends on social media and discovered that retinol is the most searched cosmeceutical on several platforms.

Investigators used analytics from TikTok and Google Trends. It is estimated that between 45% and 50% of adults turn to social media for skin care advice.

The authors conducted a Google Trends search from January 2004 to December 2023 in the United States. Trend lines were created for terms like retinol, bakuchiol, salicylic acid, glycolic acid, azelaic acid, hydroquinone, niacinamide, vitamin C serum, and hyaluronic acid. Then, the yearly perfect differences in relative search volume index (SVI) were calculated. The SVI is the ratio of the frequency a term is searched within a specific time relative to peak search volume during that time frame. An SVI of 100 is the peak popularity of the term. These trends were then graphed on scatterplots and compared to the total number of TikTok views for each search term.

The largest twofold increase in cosmeceutical search volume occurred from 2020 to 2021, due to the COVID-19 pandemic. Here, the average SVI doubled or tripled, with some increasing by 40% or more. Between 2022 and 2023, search volume rose by over 18%. This search interest in trends will continue to increase over time, according to the data.

Retinol was the most popular on both platforms followed by hyaluronic acid, salicylic acid, glycolic acid, vitamin C, niacinamide, hydroquinone, and azelaic acid. Retinol had an interest rank of 1 based on both Google SVI and TikTok views, the highest of all the cosmeceuticals. Bakuchiol was the least popular search term. Interestingly, niacinamide had much more TikTok views than Google searches. Conversely, salicylic acid had a higher Google SVI and a lower amount of TikTok viewership.

“Although not perfectly aligned, these data results collectively reveal that cosmeceutical appeal is constantly increasing, and that interest correlates with consumer viewership on social media,” the authors wrote.

The data may not accurately characterize all of the public interest due to some study limitations, including the lack of Internet access for older populations or those with lower socioeconomic status. Additionally, although Google Trends can be localized to certain geographic regions, TikTok cannot. Future literature could further evaluate specific demographics.

These results emphasize patients’ public interest in skin care, specifically with cosmeceuticals. Clinicians are advised to stay informed on popular social media trends so that they can educate their patients on product usage and combat misinformation.

“Awareness of skincare trends and growth in cosmeceutical interest empower dermatologists to anticipate patient inquiries and develop targeted education on product efficacy, cost effectiveness, and potential adverse reactions,” the authors wrote.

Let us know your thoughts and experiences by answering our poll above and commenting on social media, or by writing to us at 

1. Correia E, Mandel J, Cullison SRJ. Analyzing Social Media Trends in Cosmeceuticals: Insights From Google Trends and TikTok Analytics. 

. 2025;24(4):e70172. doi:10.1111/jocd.70172

2. Yousaf A, Hagen R, Delaney E, Davis S, Zinn Z. The influence of social media on acne treatment: A cross-sectional survey. 

2020;37(2):301-304. doi:10.1111/pde.14091

A study analyzed cosmeceutical trends on social media, revealing retinol as the most searched term on platforms like TikTok and Google. The research utilized Google Trends data from 2004 to 2023, showing a significant increase in search volume during the COVID-19 pandemic. Retinol, hyaluronic acid, and salicylic acid were among the top searched terms. The study highlights the growing public interest in cosmeceuticals and suggests that clinicians should stay informed about social media trends to educate patients effectively and address misinformation.

Google search trends and TikTok view counts were used to analyze the public popularity of cosmeceutical ingredients like retinol, hyaluronic acid, and niacinamide.

POLL: Which Cosmeceuticals Are Most Popular, According to Social Media?

This week is Hidradenitis Suppurativa Awareness Week.

POLL: What Percentage of the Population Has Hidradenitis Suppurativa?

 (Dupixent; Regeneron and Sanofi) for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who have not previously reached controlled disease status with H1 antihistamine treatment.

The approval marks the introduction of the first targeted therapy for CSU in more than a decade.

“[Dupilumab] is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over 10 years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark symptoms of intense itch and unpredictable hives associated with this disease," said George D. Yancopoulos, MD, PhD,  board co-chair, president, and chief scientific officer at Regeneron. "With this FDA decision, [dupilumab] is now approved for 7 chronic, debilitating atopic conditions driven in part by underlying type 2 inflammation, several of which have been shown to co-morbidly occur with CSU, such as atopic dermatitis and asthma – providing patients with one treatment that might help multiple atopy conditions. We look forward to bringing [dupilumab] to the more than 300,000 CSU patients in the US with inadequately controlled disease on standard-of-care treatment who, until now, had limited treatment options.”

Dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor, has already been approved for multiple type 2 inflammatory conditions, including atopic dermatitis, asthma, eosinophilic esophagitis, and prurigo nodularis.

The approval comes after years of research and regulatory engagement. In October 2023, the 

 for the initial supplemental Biologics License Application (sBLA),

 stating that additional efficacy data were needed to support approval. However, the agency did not identify concerns regarding dupilumab’s safety or manufacturing process.

In response to the CRL, Regeneron and Sanofi resubmitted the sBLA, which was 

 That resubmission included updated efficacy and safety data from a third phase 3 trial, LIBERTY-CUPID Study C, in biologic-naïve patients with CSU uncontrolled by antihistamines.

LIBERTY-CUPID: Building the Case for Approval

The LIBERTY-CUPID (NCT04180488) clinical development program, which supported the approval, consisted of 3 randomized, double-blind, placebo-controlled phase 3 trials.

: Conducted in biologic-naïve CSU patients whose symptoms remained uncontrolled despite H1 antihistamine therapy.

: Conducted in patients who were not only uncontrolled on H1 antihistamines but also refractory or intolerant to omalizumab (Xolair; Novartis).

Across the trials, patients receiving dupilumab experienced significant improvements in CSU symptoms. In Study C, which provided the pivotal data for approval, nearly half of participants achieved well-controlled disease status, marked by meaningful reductions in itch severity and hives, compared with placebo. These findings aligned with earlier results seen in Study A, reinforcing the drug’s efficacy.

Adverse events observed during the studies were consistent with dupilumab’s known safety profile. The most common adverse effects included injection site reactions and COVID-19 infections, which occurred in both treatment and placebo groups. No new safety signals were identified.

Filling a Decade-Long Gap in CSU Treatment

Prior to today’s approval, patients with CSU who did not respond to H1 antihistamines had limited treatment options, most notably omalizumab, an anti-IgE monoclonal antibody.

Dupilumab’s approval fills this gap as the first new targeted therapy for CSU in more than 10 years, and the only approved biologic that inhibits IL-4 and IL-13 signaling, key drivers of type 2 inflammation.

"It’s been 10 years with no innovation for chronic urticaria… now to switch gears for a new approval that the dermatology specialists are familiar with… ultimately, the patients benefit," said Jason Hawkes, MD, MS, a board-certified dermatologist and co-owner, chief scientific officer, and investigator at the Oregon Medical Research Center in Portland, Oregon, in a 

"Most of these patients—around 50%—don’t respond to antihistamines, even at high-doses," Hawkes added.

The companies are expected to launch Dupixent for CSU in the near future.

"It's going to bring patients into a specialty dermatology that hasn't really been managing these patients. We're going to pick up new observations, new insights," Hawkes said. "Dermatology specialists are familiar and comfortable with this therapy. They use it for other indications, but now they have a familiar therapy for a disease that they know how to recognize but weren't historically treating. I think [dupilumab] comes into that landscape where they
have the comfort with the therapy that's had a very good safety record having, in some indications, approval down to even 6 months of age."

Dupixent® (dupilumab) approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria (CSU). News release. Globe Newswire. April 18, 2025. Accessed April 18, 2025. 

https://www.globenewswire.com/news-release/2025/04/18/3064133/0/en/Dupixent-dupilumab-Approved-in-the-U-S-as-the-First-New-Targeted-Therapy-in-Over-a-Decade-for-Chronic-Spontaneous-Urticaria-CSU.html

Regeneron and Sanofi provide update on Dupixent (dupilumab) SBLA for chronic spontaneous urticaria. News release. Regeneron Pharmaceuticals Inc. October 20, 2023. Accessed April 18, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-dupixentr-dupilumab-sbla

Dupixent (dupilumab) sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (CSU). News release. Regeneron. November 15, 2024. Accessed April 18, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-review-treatment-chronic

Dupilumab for the treatment of chronic spontaneous urticaria in patients who remain symptomatic despite the use of H1 antihistamine and who are naïve to, intolerant of, or incomplete responders to omalizumab (LIBERTY-CSU CUPID). ClinicalTrials.gov ID NCT04180488. Last updated December 11, 2024. Accessed April 18, 2025. 

https://clinicaltrials.gov/ct2/show/NCT04180488

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Miranda Uzoma Ewelukwa, MD, FAAD

Articles

Latest Updated Articles